{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:28:52Z","timestamp":1787776132907,"version":"build-2784847793"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n This study aimed to identify the predictors of liver decompensation and mortality in patients with HCC treated with trans arterial radioembolization (TARE).<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n A retrospective analysis of 140 HCC patients who underwent TARE was conducted. Kaplan\u2010Meier and multivariate Cox regression analyses were performed to identify the key predictors of mortality and liver decompensation, defined as a total bilirubin level greater than 50 \u03bcmol\/l or an upgrade in the Child\u2010Pugh class within three months of the first TARE procedure.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n The cohort comprised 69.3% males with a mean age of 71.3 \u00b1 11.9 years. Most patients (73.6%) had Child-Pugh class A cirrhosis and 34.3% had BCLC stage B disease. Liver decompensation was recorded in 55 patients (39.2%) within three months of the first TARE procedure. A total of 80 patients (57.1%) died during the follow-up period. The median survival was significantly longer in those without liver decompensation (3.2 vs. 0.7 years,\n P<\/jats:italic>\n < 0.001). Multivariate analysis revealed that male gender (adjusted odds ratio [aOR] 5.889,\n P<\/jats:italic>\n = 0.009), cirrhosis (aOR 6.82,\n P<\/jats:italic>\n = 0.047), and baseline international normalized ratio (INR) (aOR 316.664,\n P<\/jats:italic>\n = 0.013) were independent predictors of liver decompensation. Cox regression analysis revealed several significant predictors of increased mortality including ascites (HR 2.012, 95% CI, 1.122\u20133.61;\n P<\/jats:italic>\n = 0.019), portal vein invasion (HR 1.695, 95% CI, 1.057\u20132.718;\n P<\/jats:italic>\n = 0.029), and diabetes mellitus (HR 1.823, 95% CI, 1.017\u20133.265;\n P<\/jats:italic>\n = 0.044). Conversely, non-multifocal HCC (HR 0.593, 95% CI, 0.369\u20130.955;\n P<\/jats:italic>\n = 0.031), treatment of the liver lobe other than the right lobe (HR, 0.482; 95% CI 0.236\u20130.986,\n P<\/jats:italic>\n = 0.046), and age \u226560 years (HR 0.288, 95% CI, 0.139\u20130.597;\n P<\/jats:italic>\n = 0.001) were associated with a reduced risk of mortality.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n This study identified the key predictors of liver decompensation and mortality in patients with HCC undergoing TARE, potentially improving patient selection and management strategies.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/sjg.sjg_343_24","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T03:00:17Z","timestamp":1741316417000},"page":"176-184","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Identifying key predictors of mortality and liver decompensation in hepatocellular carcinoma patients treated with transarterial radioembolization"],"prefix":"10.4103","volume":"31","author":[{"given":"Mohammad","family":"Arabi","sequence":"first","affiliation":[{"name":"Department of Medical Imaging, Division of Vascular and Interventional Radiology, King Abdulaziz Medical City-Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"},{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdan S.","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"},{"name":"Department of Hepatobiliary Sciences and Organ Transplantation, Hepatology Section, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz A.","family":"Almesned","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar I.","family":"Alanazi","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Division of Vascular and Interventional Radiology, King Abdulaziz Medical City-Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia"},{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meshari A.","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Bukhaytan","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed F.","family":"Alkhalaf","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muath A.","family":"Almaimoni","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaf A.","family":"Alagrafy","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhan K.","family":"Alanazi","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia"},{"name":"King Abdullah International Medical Research Center, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"key":"R1-20250519","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"R2-20250519","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation:The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"R3-20250519","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"R4-20250519","first-page":"103","article-title":"Is the Y90-radioembolization treatment effective on the intermediate-advanced stage of hepatocellular carcinoma and what is the albumin-bilirubin score's prediction factor for survival?Hepatol Forum","volume":"4","author":"Evirgen","year":"2023"},{"key":"R5-20250519","doi-asserted-by":"crossref","first-page":"9926704","DOI":"10.1155\/2021\/9926704","article-title":"Predictors of successful Yttrium-90 radioembolization bridging or downstaging in patients with hepatocellular carcinoma","volume":"2021","author":"Villalobos","year":"2021","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R6-20250519","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC:The LEGACY study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"R7-20250519","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jvir.2021.03.535","article-title":"Multicenter evaluation of survival and toxicities of hepatocellular carcinoma following radioembolization:Analysis of the RESiN registry","volume":"32","author":"Frantz","year":"2021","journal-title":"J Vasc Interv Radiol"},{"key":"R8-20250519","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s00534-010-0314-0","article-title":"Anew classification for hepatocellular carcinoma with portal vein tumor thrombus","volume":"18","author":"Shi","year":"2011","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R9-20250519","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jvir.2024.10.034","article-title":"Yttrium-90 radioembolization has become the most utilized bridging treatment for liver transplant candidates in the United States","volume":"36","author":"Salem","year":"2025","journal-title":"J Vasc Interv Radiol"},{"key":"R10-20250519","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/MEG.0000000000000772","article-title":"Radioembolization-induced liver disease:A systematic review","volume":"29","author":"Braat","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R11-20250519","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s00270-023-03391-4","article-title":"Predictive factors for adverse event outcomes after transarterial radioembolization with yttrium-90 resin microspheres in europe:Results from the prospective observational CIRT study","volume":"46","author":"Maleux","year":"2023","journal-title":"Cardiovasc Intervent Radiol"},{"key":"R12-20250519","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1002\/hep4.2072","article-title":"Hepatic decompensation after transarterial radioembolization:A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma","volume":"6","author":"Reincke","year":"2022","journal-title":"Hepatol Commun"},{"key":"R13-20250519","doi-asserted-by":"crossref","first-page":"100633","DOI":"10.1016\/j.jhepr.2022.100633","article-title":"Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma:Results from the prospective CIRT study","volume":"5","author":"Kolligs","year":"2023","journal-title":"JHEP Rep"},{"key":"R14-20250519","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archsurg.2011.288","article-title":"The effect of age on the long-term prognosis of patients with hepatocellular carcinoma after resection surgery:A propensity score matching analysis","volume":"147","author":"Su","year":"2012","journal-title":"Arch Surg"},{"key":"R15-20250519","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3892\/ol.2024.14544","article-title":"Prognostic analysis of systemic antitumor therapy in young patients with advanced liver cancer:A cohort study","volume":"28","author":"Zhang","year":"2024","journal-title":"Oncol Lett"},{"key":"R16-20250519","doi-asserted-by":"crossref","first-page":"261","DOI":"10.7150\/ijbs.66536","article-title":"Identification and validation of a prognostic model based on three MVI-related genes in hepatocellular carcinoma","volume":"18","author":"Tang","year":"2022","journal-title":"Int J Biol Sci"},{"key":"R17-20250519","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1186\/s12885-021-08904-3","article-title":"Survival improvement and prognosis for hepatocellular carcinoma:Analysis of the SEER database","volume":"21","author":"Ding","year":"2021","journal-title":"BMC Cancer"},{"key":"R18-20250519","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1007\/s10620-024-08549-9","article-title":"Clinical characteristics and prognosis of early-onset hepatocellular carcinoma:A retrospective cohort study based on population data","volume":"69","author":"Guan","year":"2024","journal-title":"Dig Dis Sci"},{"key":"R19-20250519","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.21037\/jgo-22-882","article-title":"Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma","volume":"14","author":"Lee","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"R20-20250519","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12885-022-09293-x","article-title":"The survival strength of younger patients in BCLC stage 0-B of hepatocellular carcinoma:Basing on competing risk model","volume":"22","author":"Yan","year":"2022","journal-title":"BMC Cancer"},{"key":"R21-20250519","doi-asserted-by":"crossref","first-page":"e2435066","DOI":"10.1001\/jamanetworkopen.2024.35066","article-title":"Survival outcomes among patients with hepatocellular carcinoma in a large integrated US health system","volume":"7","author":"Yilma","year":"2024","journal-title":"JAMA Netw Open"},{"key":"R22-20250519","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"(90)Y radioembolization versus drug-eluting bead chemoembolization for unresectable hepatocellular carcinoma:Results from the TRACE phase II randomized controlled trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"R23-20250519","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01):A randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R24-20250519","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3390\/diagnostics12040834","article-title":"Segmental distribution of hepatocellular carcinoma in cirrhotic livers","volume":"12","author":"Renzulli","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R25-20250519","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12957-020-02100-6","article-title":"Is left-sided involvement of hepatocellular carcinoma an important preoperative predictive factor of poor outcome?","volume":"18","author":"Sakuraoka","year":"2020","journal-title":"World J Surg Oncol"},{"key":"R26-20250519","doi-asserted-by":"crossref","first-page":"089","DOI":"10.1055\/s-0039-1694091","article-title":"Vascular redistribution for SIRT\u2014A quantitative assessment of treatment success and long-term analysis of recurrence and survival outcomes","volume":"03","author":"Borg","year":"2019","journal-title":"J Clin Interv Radiol ISVIR"},{"key":"R27-20250519","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/cncr.23339","article-title":"Liver disease induced by radioembolization of liver tumors:Description and possible risk factors","volume":"112","author":"Sangro","year":"2008","journal-title":"Cancer"},{"key":"R28-20250519","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.26191","article-title":"Prognostic factors and prevention of radioembolization-induced liver disease","volume":"57","author":"Gil-Alzugaray","year":"2013","journal-title":"Hepatology"},{"key":"R29-20250519","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.3390\/diagnostics13243652","article-title":"Prophylactic medication during radioembolization in metastatic liver disease:Is it really necessary?a retrospective cohort study and systematic review of the literature","volume":"13","author":"Braat","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R30-20250519","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.3390\/cancers15174274","article-title":"Bilobar radioembolization carries the risk of radioembolization-induced liver disease in the treatment of advanced hepatocellular carcinoma:Safety and efficacy comparison to systemic therapy with atezolizumab\/bevacizumab","volume":"15","author":"Jeschke","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R31-20250519","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","article-title":"Aglobal evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with yttrium-90:The TARGET study","volume":"49","author":"Lam","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R32-20250519","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.jvir.2018.07.006","article-title":"Tumor targeting and three-dimensional voxel-based dosimetry to predict tumor response, toxicity, and survival after Yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma","volume":"29","author":"Allimant","year":"2018","journal-title":"J Vasc Interv Radiol"},{"key":"R33-20250519","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2967\/jnumed.110.075861","article-title":"Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres:Radiobiologic considerations","volume":"51","author":"Strigari","year":"2010","journal-title":"J Nucl Med"},{"key":"R34-20250519","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00259-023-06111-9","article-title":"Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization:A prospective, single-arm study","volume":"50","author":"Kokabi","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R35-20250519","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","article-title":"International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres","volume":"48","author":"Levillain","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_343_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:50:32Z","timestamp":1787773832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_343_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_343_24","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"2024-09-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}